Stroma liquid biopsy™-a proteomic model of the systemic response to cancer

Abstract

The advancements in “nextgen” and rapid genome sequencing have spawned new companies for liquid biopsy products and services that are quick, minimally invasive and that allow clinicians to monitor the course of therapy and to forecast recurrent disease. While these are certainly exciting prospects, challenges remain as genomic instability is a fundamental hallmark of cancer cells [1]. So in many respects, genomic driven approaches will always suffer the problem of shooting after a moving target.